The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study
Abstract
Background— The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction. We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome. Methods and Results— We randomized 58 subjects with the metabolic syndrome in a double-blinded manner to irbesartan 150 mg/d (n=14), lipoic acid 300 mg/d (n=15), both irbesartan and lipoic acid (n=15), or matching placebo (n=14) for 4 weeks. Endothelium-dependent and -independent flow-mediated vasodilation was determined under standard conditions. Plasma levels of interleukin-6, plasminogen activator-1, and 8-isoprostane were measured. After 4 weeks of therapy, endothelium-dependent flow-mediated vasodilation of the brachial artery was increased by 67%, 44%, and 75% in the irbesartan, lipoic acid, and irbesartan plus lipoic acid groups, respectively, compared with the placebo group. Treatment with irbesartan and/or lipoic acid was associated with statistically significant reductions in plasma levels of interleukin-6 and plasminogen activator-1. In addition, treatment with irbesartan or irbesartan plus lipoic acid decreased 8-isoprostane levels. No significant changes in blood pressure were noted in any of the study groups. Conclusions— Administration of irbesartan and/or lipoic acid to patients with the metabolic syndrome improves endothelial function and reduces proinflammatory markers, factors that are implicated in the pathogenesis of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Corretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D., Charbonneau, F., Creager, M. A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01746-6 · Cited by 4,604
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,358
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Atherosclerosis is an inflammatory disease
Ross, R. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70266-8 · Cited by 1,451
Schmidt, M. I., Duncan, B. B., Sharrett, A. R., Lindberg, G., Savage, P. J., Offenbacher, S., Azambuja, M. I., Tracy, R. P., & Heiss, G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01046-6 · Cited by 1,071
Warnholtz, A., Nickenig, G., Schulz, E., Macharzina, R., Bräsen, J. H., Skatchkov, M., Heitzer, T., Stasch, J. P., Griendling, K. K., Harrison, D. G., et al. (1999) · Circulation · doi:10.1161/01.cir.99.15.2027 · Cited by 676
Cited by
Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential
Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.026 · Cited by 976
Pisoschi, A. M., Pop, A., Iordache, F., Stanca, L., Predoi, G., & Serban, A. I. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112891 · Cited by 816
Endothelial dysfunction — A major mediator of diabetic vascular disease
Sena, C. M., Pereira, A. M., & Seiça, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.006 · Cited by 797
Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy
Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., et al. (2006) · Diabetes Care · doi:10.2337/dc06-1216 · Cited by 562
Role of insulin resistance in endothelial dysfunction
Muniyappa, R., & Sowers, J. R. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9229-1 · Cited by 539
Metadata
- Authors
- Sola, S., Mir, M. Q. S., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S., & Khan, B. V.
- Venue
- Circulation
- Published
- 2005-01-25
- Volume
- 111
- Issue
- 3
- Pages
- 343-348
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2078600320
- Cited by
- 282
- References
- 38
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study. https://app.cochat.ai/papers/10.1161/01.cir.0000153272.48711.b9
- The paper
- Sola, S., Mir, M. Q. S., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S., & Khan, B. V. (2005). Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study. Circulation. https://doi.org/10.1161/01.cir.0000153272.48711.b9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.